Press Review… Autumn 2024 Press Review – Seminars in Arthritis and Rheumatism 8 Oct 20249 Oct 2024 APRIL 2024 to JULY 2024 Author: Guillermo Carvajal Alegria & Miranda van Lunteren Seminars in Arthritis and Rheumatism Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis…
Tell Me Something Interesting Tell me something interesting 8 Oct 2024 In the August issue, we introduced you to the paper of Pierre-Antoine Juge et al. about the participation of junior members in EULAR task forces. In fact, junior scientists are…
EMEUNET Committee and Sub-Commitee New Members of the EMEUNET Sub-Committees 2024-2025 2 Sep 20243 Sep 2024 Links to other EMEUNET Sub-Committee membership posts: EMEUNET Committee members Continuing EMEUNET Sub-Committee members Farewell to EMEUNET Sub-Committee members Dr Rym Abida Countries: Tunisia, UK Rym is a specialty doctor who graduated…
EULAR 2024 Highlights… EULAR 2024 Highlights – SLE and APS 21 Jul 202422 Jul 2024 Author: Cristiana Sieiro Santos Taubmann et al. (OP0027) presented data on the long-term safety and efficacy of autologous CD19 CAR T cell therapy in patients with SLE, IIM and SSc, showing that…
Connective Tissue Diseases and Vasculitis… EULAR 2024 Highlights – Vasculitis and other Connective Tissue Diseases 21 Jul 202422 Jul 2024 Author: Jan Schirmer Blockmans et al. (LBA0001) reported the results of the SELECT-GCA trial that compared Upadacitinib (either 15 or 7.5 mg daily combined with a 26 week prednisone taper)…
EULAR 2024 Highlights… EULAR 2024 Highlights – RA I – Clinical (non-therapeutic) 21 Jul 202421 Jul 2024 Author: Dálifer Freites Núñez Gerritsen et al. (POS0652) created a prediction model based on volatile organic compounds (VOCs) in exhaled breath to differentiate between patients with rheumatoid arthritis (RA) and…
EULAR 2024 Highlights… EULAR 2024 Highlights – RA II – Clinical (therapeutic) 21 Jul 202421 Jul 2024 Author: Daliya Pencheva Aymon et al. (OP0092) assessed the incidence of infections in rheumatoid arthritis (RA) patients from 14 RA registries in the JAK-POT study. Data from 54,905 treatment initiations,…
EULAR 2024 Highlights… EULAR 2024 Highlights – Spondyloarthritis I – non-therapeutic 21 Jul 202421 Jul 2024 Author: Bayram Farisogullari Da Silva et al. (POS0005) compared the spinal symptoms at baseline and after two years in early axial spondyloathritis (axSpA) patients (n = 267) and non-axSpA chronic…
EULAR 2024 Highlights… EULAR 2024 Highlights – Spondyloarthritis II – therapeutic 21 Jul 202421 Jul 2024 Author: Jean-Guillaume Letarouilly Webers et al. (OP0060) investigated which ASDAS cut-off values correspond best with treatment intensification (TI) in practice through the prospective multicentre Dutch registry for patients with SpA…
Basic and Translational Research… EULAR 2024 Highlights- Basic and Translational Research 21 Jul 202422 Jul 2024 Author: Giacomo Cafaro Toitou et al. (OP0056) investigated the biology of CD74+ synovial fibroblasts (SF) in rheumatoid arthritis (RA) and found that RA T-cells are able to induce the expression…